F.D.A. Requests Federal Investigation of Alzheimer’s Drug Approval

The agency’s acting head said a review should look into whether any interactions between agency staff and the drug developer, Biogen, broke F.D.A. rules. News & more most reading Infos >> Ukraine RussiaUkraine Russia Infos

News & more most reading Infos >> Ukraine Russia

In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms. News & more most reading Infos >> Ukraine RussiaUkraine […]

News & more most reading Infos >> Ukraine Russia

Biogen’s Alzheimer’s Drug Poses a Dilemma for the F.D.A.

If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. News & more most […]

News & more most reading Infos >> Ukraine Russia

F.D.A. Approves Alzheimer’s Drug Despite Fierce Debate Over Whether It Works

Aducanumab is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms. News & more […]

News & more most reading Infos >> Ukraine Russia

Alzheimer’s Drug Poses a Dilemma for the F.D.A.

If the agency approves it, aducanumab would be the first new Alzheimer’s treatment since 2003. Patients are desperate for new options, but some scientists say there isn’t enough evidence it works. News & more most […]

News & more most reading Infos >> Ukraine Russia